US 12,472,169 B2
Method for treating movement disorders with befiradol
Bruno Paillard, Escalquens (FR); Laurence Del Frari, Trebons sur la Grasse (FR); Valérie Brunner, Saint Orens de Gameville (FR); Adrian Newman Tancredi, Castres (FR); and Mark Varney, Dana Point, CA (US)
Assigned to PIERRE FABRE MEDICAMENT, Boulogne-Billancourt (FR)
Filed by PIERRE FABRE MEDICAMENT, Boulogne-Billancourt (FR)
Filed on Jun. 25, 2021, as Appl. No. 17/359,182.
Application 16/717,019 is a division of application No. 15/310,415, granted, now 10,548,885, issued on Feb. 4, 2020, previously published as PCT/EP2015/065763, filed on Jul. 9, 2015.
Application 17/359,182 is a continuation of application No. 16/717,019, filed on Dec. 17, 2019, granted, now 11,090,298.
Claims priority of provisional application 62/022,462, filed on Jul. 9, 2014.
Prior Publication US 2021/0338646 A1, Nov. 4, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/444 (2006.01); A61K 9/00 (2006.01); A61K 31/395 (2006.01); A61K 31/4545 (2006.01); A61K 31/495 (2006.01); A61K 47/38 (2006.01)
CPC A61K 31/444 (2013.01) [A61K 9/0053 (2013.01); A61K 31/395 (2013.01); A61K 31/4545 (2013.01); A61K 31/495 (2013.01); A61K 47/38 (2013.01)] 20 Claims
 
1. A method for treating a movement disorder in a patient in need thereof, comprising administering to the patient an effective amount of befiradol or a pharmaceutically acceptable derivative thereof, wherein the administering step provides an average patient's maximum plasma concentration of befiradol below about 15 ng/ml, which occurs more than about 4 hours post administration, said method minimizing side effects of dizziness and nausea,
wherein the pharmaceutically acceptable derivative of befiradol is an isotopic form, a salt, a solvate, an ester, a prodrug, or a crystal form,
wherein no additional active ingredient is administered during the administering step.